Insider Transactions Reported by 17 Insiders of NovaBay Pharmaceuticals, Inc.

Symbol
NBY on NYSE
Location
Emeryville, CA

Sponsored

Insiders trading volume in the past year

Insider trading buckets (0-12 months)

NovaBay Pharmaceuticals, Inc. executives and other stock owners filed with the SEC include:

Name Relationship Holdings Value Past Year Net Change Change % Valuation Report Date
Framework Ventures IV L.P. 10%+ Owner $74,228,504 Mixed 16 Oct 2025
R01 Fund LP 10%+ Owner $74,228,504 Mixed 16 Oct 2025
Michael John Kazley Chief Executive Officer, Director, 10%+ Owner $74,228,504 Mixed 31 Mar 2026
David E. Lazar 10%+ Owner $36,028,320 Median 21 Oct 2025
POPLAR POINT CAPITAL PARTNERS LP 10%+ Owner $474,440 +$140 +0.03% Filing P/S 02 Apr 2025
Andrew D. Jones Cfo $230,704 Mixed 15 Feb 2023
Justin Hall CEO, GC and Director, Director $150,541 Mixed 14 Sep 2022
Yongxiang Zheng Director $54,300 Mixed 28 May 2024
Yenyou Zheng Director $54,300 Mixed 28 May 2024
Julie Garlikov Director $54,300 Mixed 28 May 2024
Xinzhou Li Director, 10%+ Owner $54,300 Mixed 21 May 2021
Paul E. Freiman Director $54,300 Mixed 28 May 2024
Mijia Wu Director $54,300 Mixed 28 May 2024
Swan Sit Director $54,300 Mixed 31 Mar 2026
Tommy Law Interim CFO Mixed 16 Feb 2023
Jeffrey Kunin President, DERMAdoctor, LLC Mixed 06 Dec 2022
Audrey Kunin Chief Product Officer Mixed 06 Dec 2022

Recent Insider Transactions by Companies or Individuals for NovaBay Pharmaceuticals, Inc.

Showing up to 300 most recent insider transactions from the last 12 months.

Insider Symbol Class Transaction % Value $ * Price $ Shares Shares Owned Date Ownership
Michael John Kazley NBY Restricted Stock Units (Performance-Based) Award 7,722,802 7,722,802 31 Mar 2026 Direct
Michael John Kazley NBY Restricted Stock Units (Time-Based) Award 4,118,828 4,118,828 31 Mar 2026 Direct
Swan Sit NBY Restricted Stock Units Award 140,000 140,000 31 Mar 2026 Direct
David E. Lazar NBY Common Stock Award 6,388,000 6,388,000 21 Oct 2025 Direct
David E. Lazar NBY Series D Convertible Preferred Stock Options Exercise -100% -39,925 0 21 Oct 2025 Direct
Framework Ventures IV L.P. NBY Common Stock Conversion of derivative security 56,806,080 56,806,080 21 Oct 2025 Direct
R01 Fund LP NBY Common Stock Conversion of derivative security 56,806,080 56,806,080 21 Oct 2025 Direct
Michael John Kazley NBY Common Stock Conversion of derivative security 56,806,080 56,806,080 21 Oct 2025 By R01 Entities
Framework Ventures IV L.P. NBY Pre-Funded Warrants (Right to Buy) Purchase 2,702,703 2,702,703 16 Oct 2025 Direct
R01 Fund LP NBY Pre-Funded Warrants (Right to Buy) Purchase 2,702,703 2,702,703 16 Oct 2025 Direct
Michael John Kazley NBY Pre-Funded Warrants (Right to Buy) Purchase 2,702,703 2,702,703 16 Oct 2025 By R01 Entities
Framework Ventures IV L.P. NBY Series E Non-Voting Convertible Preferred Stock Other 134,375 134,375 16 Oct 2025 Direct
Framework Ventures IV L.P. NBY Series D Non-Voting Convertible Preferred Stock Other 220,663 220,663 16 Oct 2025 Direct
Michael John Kazley NBY Series E Non-Voting Convertible Preferred Stock Award 134,375 134,375 16 Oct 2025 By R01 Entities
Michael John Kazley NBY Series D Non-Voting Convertible Preferred Stock Award 220,663 220,663 16 Oct 2025 By R01 Entities
R01 Fund LP NBY Series E Non-Voting Convertible Preferred Stock Award 134,375 134,375 16 Oct 2025 Direct
R01 Fund LP NBY Series D Non-Voting Convertible Preferred Stock Award 220,663 220,663 16 Oct 2025 Direct
David E. Lazar NBY Series D Convertible Preferred Stock Sale -91.7% -441,325 39,925 16 Oct 2025 Direct
Poplar Point Capital Partners Lp NBY Common Stock, par value $0.01 per share Purchase 0.03% $140 $0.4650 300 1,020,300 08 Apr 2025 Direct
Poplar Point Capital Partners Lp NBY Common Stock, par value $0.01 per share Purchase 0.45% $2,367 $0.5216 4,538 1,020,000 04 Apr 2025 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Sponsored